Gujarat Themis Biosyn Reports Decline in Key Financial Metrics for August 2025

Gujarat Themis Biosyn, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 1, 2025, indicate a notable shift in the company's financial performance, leading to an adjustment in its evaluation.
The Profit Before Tax less Other Income (PBT) for the quarter stands at Rs 11.85 crore, reflecting a decline compared to the average of the previous four quarters. Similarly, the Profit After Tax (PAT) has also shown a downward trend, recorded at Rs 9.06 crore, which is lower than the average PAT from the last four quarters. The Operating Profit, at Rs 13.91 crore, marks the lowest figure in the past five quarters, suggesting challenges in maintaining operational efficiency.

Additionally, the Operating Profit Margin has reached its lowest point at 38.78%, indicating a shift in the company's efficiency metrics. The Earnings per Share (EPS) has also decreased to Rs 0.83, highlighting a reduction in profitability for shareholders. These financial results have prompted a revision in the stock's score, reflecting the current challenges faced by Gujarat Themis Biosyn.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.